Paolo Tarantino/X
Jun 1, 2025, 16:37
Paolo Tarantino Shares DB06 Biomarker Analysis Insights from ASCO 2025
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post by Luiza Pamela Beato, Medical Oncology Resident, posted on X:
“Biomarker analyses from DB06 presented by Rebecca Dent.
As expected, the benefit of T-DXd over chemo is seen irrespective of tumor genomics (similar to DB04). Most dramatic benefit in the BRCAmut subset, though small numbers and in contrast with other trials (DB03/DB04/RWD).”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 11:05
Jul 19, 2025, 10:29
Jul 19, 2025, 10:12
Jul 19, 2025, 09:55
Jul 19, 2025, 09:05
Jul 19, 2025, 08:54
Jul 19, 2025, 07:24
Jul 19, 2025, 07:23